Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Faulkner, L. Harding, H. Chrystyn (Huddersfield, United Kingdom). In-vitro comparison of tobramycin nebulised using two different nebuliser systems. Eur Respir J 2010; 36: Suppl. 54, 2032

Member's Comments

No comment yet.

Related content which might interest you: The effect of nebulizer systems in inhaled tobramycin Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Relative lung deposition of tobramycin from a MicroAir nebuliser Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006 Physicochemical compatibility of ipratropium, albuterol and fluticasone nebulizer solutions Source: Eur Respir J 2006; 28: Suppl. 50, 211s Year: 2006 In-vitro evaluation of pressurized metered dose inhalers in high flow oxygen system Source: Virtual Congress 2020 – Non-invasive ventilation and nasal high flow: technical aspects and predictive scores Year: 2020 In-vitro nebulised dose emission characteristics of a tobramycin solution (75mg/ml) using an I-Neb (I-NEB) and a pari LC+ driven by a TurboBoy compressor (PARI) nebuliser Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Clinical pharmacology study of a new tobramycin solution for nebulisation Source: Eur Respir J 2005; 26: Suppl. 49, 729s Year: 2005 Pharmacokinetics of instilled versus nebulized tobramycin or Imipenem in mechanically ventilated ICU patients Source: Eur Respir J 2002; 20: Suppl. 38, 16s Year: 2002 Successful conversion of patients using nebulised iloprost from multisonic nebuliser to adaptive aerosol delivery nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007 Intrapulmonal deposition of two different tobramycin formulations Source: Eur Respir J 2005; 26: Suppl. 49, 729s Year: 2005 In vitro comparison of Pulmicort Respules™ with Clenil® pro aerosol in combination with three nebulisers Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002 Distribution of nebulised gentamicin in patients with bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Pharmacokinetics of tobramycin nebulizer solution (300mg/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 Pharmacodynamic effects of nebulised bronchodilator combinations Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Comparison between salbutamol-MAGhaler and terbutaline turbohaler Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001 In-vitro deposition study of a levofloxacin (LEV) solution into a novel human nasal cast model by the PARI VibrENTÔ Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Nebulized salbutamol through the ultrasonic nebulizer during sputum induction improves the bronchoprotection in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002 Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002 Similar delivery of ipratropium bromide is possible at approximately one-half dose via a breath-actuated nebulizer compared with a continuous nebulizer Source: Eur Respir J 2005; 26: Suppl. 49, 306s Year: 2005